Novel device eases instillation of eye drops

Article

Patients who used a proprietary eye drop delivery device (Eyedrop, Vanguard Design, São Paulo, Brazil) in a pilot study reported that it eased the instillation of hypotensive drops, especially if they weren’t used to using eye drops, the study authors report in the Journal of Clinical Ophthalmology.

Patients who used a proprietary eye drop delivery device (Eyedrop, Vanguard Design, São Paulo, Brazil) in a pilot study reported that it eased the instillation of hypotensive drops, especially if they weren’t used to using eye drops, the study authors report in the Journal of Clinical Ophthalmology. Use of the plastic device, into which the medication bottle is inserted, did not change the drops’ effectiveness nor the frequency of side effects.

“The improvement in patient adherence to treatment could result in better IOP control and lower risk of progression over time,” the authors wrote. “Further studies with larger sample sizes and longer follow-up are necessary in order to better investigate such aspects.”

The study included 32 patients, 44% of whom had glaucoma. No significant difference in mean IOP variation existed between those using the device and those not using it. Patients learned how to use the device via video and a handout that included written instructions and illustrations after initially using the device under physician supervision.

The researchers are from the United States and Brazil.

 

 

 

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.